Cargando…

Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years

BACKGROUND: Metabolic bone diseases (MBD) are typically diagnosed by non-invasive imaging and clinical biomarkers. However, imaging does not provide structural information, and biomarkers can be transiently affected by many systemic factors. Bone biopsy and pathologic evaluation is the gold standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Colazo, Juan M., Quirion, Julia, Judice, Anthony D., Halpern, Jennifer, Schwartz, Herbert S., Tanner, S. Bobo, Lawrenz, Joshua M., Dahir, Kathryn M., Holt, Ginger E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558706/
https://www.ncbi.nlm.nih.gov/pubmed/37811524
http://dx.doi.org/10.1016/j.bonr.2023.101715
_version_ 1785117337363415040
author Colazo, Juan M.
Quirion, Julia
Judice, Anthony D.
Halpern, Jennifer
Schwartz, Herbert S.
Tanner, S. Bobo
Lawrenz, Joshua M.
Dahir, Kathryn M.
Holt, Ginger E.
author_facet Colazo, Juan M.
Quirion, Julia
Judice, Anthony D.
Halpern, Jennifer
Schwartz, Herbert S.
Tanner, S. Bobo
Lawrenz, Joshua M.
Dahir, Kathryn M.
Holt, Ginger E.
author_sort Colazo, Juan M.
collection PubMed
description BACKGROUND: Metabolic bone diseases (MBD) are typically diagnosed by non-invasive imaging and clinical biomarkers. However, imaging does not provide structural information, and biomarkers can be transiently affected by many systemic factors. Bone biopsy and pathologic evaluation is the gold standard for diagnosis of MBD, however, it is rarely utilized. We describe our technique for iliac crest tetracycline-labelled bone using a cannulated drill and assess the utility of bone biopsies to provide diagnostic and therapeutic guidance. METHODS: In the 25-year period between March 1998 and January 2023, a total of 95 bone biopsies were performed on 94 patients for an osteological indication at Vanderbilt University Medical Center (VUMC). Patient demographics, bone biopsy indications, complications, diagnostic utility, and subsequent therapeutic guidance were retrospectively reviewed and analyzed. RESULTS: The procedure had minimal complications and was well tolerated by patients. This technique provided good quality specimens for pathology, which helped establish a diagnosis and treatment change in most patients. Patients that had biopsy-guided treatment alterations showed significant increases in Dual-Energy X-ray Absorptiometry (DEXA) bone mineral density (BMD) scores post-biopsy and subsequent treatment. CONCLUSION: Despite scientific and technological progress in non-invasive diagnostic imaging, clinical biomarkers, and procedures for MBD, there remains a small but significant subset of patients who may benefit from inclusion of tetracycline-labelled bone biopsy into the diagnostic and therapeutic picture. Future prospective comparison studies are warranted. MINI ABSTRACT: Tetracycline-labelled bone biopsies are under-utilized. Biopsy led to a histological diagnosis and ensuing treatment alteration in most patients with significant increases in bone mineral density. The biopsy procedure used herein provided good specimens with low pain/adverse events. Bone biopsy remains a valuable tool in a small, though significant, subset of patients.
format Online
Article
Text
id pubmed-10558706
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105587062023-10-08 Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years Colazo, Juan M. Quirion, Julia Judice, Anthony D. Halpern, Jennifer Schwartz, Herbert S. Tanner, S. Bobo Lawrenz, Joshua M. Dahir, Kathryn M. Holt, Ginger E. Bone Rep Full Length Article BACKGROUND: Metabolic bone diseases (MBD) are typically diagnosed by non-invasive imaging and clinical biomarkers. However, imaging does not provide structural information, and biomarkers can be transiently affected by many systemic factors. Bone biopsy and pathologic evaluation is the gold standard for diagnosis of MBD, however, it is rarely utilized. We describe our technique for iliac crest tetracycline-labelled bone using a cannulated drill and assess the utility of bone biopsies to provide diagnostic and therapeutic guidance. METHODS: In the 25-year period between March 1998 and January 2023, a total of 95 bone biopsies were performed on 94 patients for an osteological indication at Vanderbilt University Medical Center (VUMC). Patient demographics, bone biopsy indications, complications, diagnostic utility, and subsequent therapeutic guidance were retrospectively reviewed and analyzed. RESULTS: The procedure had minimal complications and was well tolerated by patients. This technique provided good quality specimens for pathology, which helped establish a diagnosis and treatment change in most patients. Patients that had biopsy-guided treatment alterations showed significant increases in Dual-Energy X-ray Absorptiometry (DEXA) bone mineral density (BMD) scores post-biopsy and subsequent treatment. CONCLUSION: Despite scientific and technological progress in non-invasive diagnostic imaging, clinical biomarkers, and procedures for MBD, there remains a small but significant subset of patients who may benefit from inclusion of tetracycline-labelled bone biopsy into the diagnostic and therapeutic picture. Future prospective comparison studies are warranted. MINI ABSTRACT: Tetracycline-labelled bone biopsies are under-utilized. Biopsy led to a histological diagnosis and ensuing treatment alteration in most patients with significant increases in bone mineral density. The biopsy procedure used herein provided good specimens with low pain/adverse events. Bone biopsy remains a valuable tool in a small, though significant, subset of patients. Elsevier 2023-09-24 /pmc/articles/PMC10558706/ /pubmed/37811524 http://dx.doi.org/10.1016/j.bonr.2023.101715 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Full Length Article
Colazo, Juan M.
Quirion, Julia
Judice, Anthony D.
Halpern, Jennifer
Schwartz, Herbert S.
Tanner, S. Bobo
Lawrenz, Joshua M.
Dahir, Kathryn M.
Holt, Ginger E.
Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years
title Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years
title_full Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years
title_fullStr Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years
title_full_unstemmed Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years
title_short Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years
title_sort utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: an evaluation of 95 cases over a period of 25 years
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558706/
https://www.ncbi.nlm.nih.gov/pubmed/37811524
http://dx.doi.org/10.1016/j.bonr.2023.101715
work_keys_str_mv AT colazojuanm utilityofiliaccresttetracyclinelabelledbonebiopsyinosteoporosisandmetabolicbonediseaseanevaluationof95casesoveraperiodof25years
AT quirionjulia utilityofiliaccresttetracyclinelabelledbonebiopsyinosteoporosisandmetabolicbonediseaseanevaluationof95casesoveraperiodof25years
AT judiceanthonyd utilityofiliaccresttetracyclinelabelledbonebiopsyinosteoporosisandmetabolicbonediseaseanevaluationof95casesoveraperiodof25years
AT halpernjennifer utilityofiliaccresttetracyclinelabelledbonebiopsyinosteoporosisandmetabolicbonediseaseanevaluationof95casesoveraperiodof25years
AT schwartzherberts utilityofiliaccresttetracyclinelabelledbonebiopsyinosteoporosisandmetabolicbonediseaseanevaluationof95casesoveraperiodof25years
AT tannersbobo utilityofiliaccresttetracyclinelabelledbonebiopsyinosteoporosisandmetabolicbonediseaseanevaluationof95casesoveraperiodof25years
AT lawrenzjoshuam utilityofiliaccresttetracyclinelabelledbonebiopsyinosteoporosisandmetabolicbonediseaseanevaluationof95casesoveraperiodof25years
AT dahirkathrynm utilityofiliaccresttetracyclinelabelledbonebiopsyinosteoporosisandmetabolicbonediseaseanevaluationof95casesoveraperiodof25years
AT holtgingere utilityofiliaccresttetracyclinelabelledbonebiopsyinosteoporosisandmetabolicbonediseaseanevaluationof95casesoveraperiodof25years